ProQR Therapeutics (PRQR) EBIAT (2013 - 2025)
ProQR Therapeutics recorded quarterly EBIAT of -$10.4 million in Q4 2025, up 19.3% quarter-over-quarter from -$12.9 million in Q3 2025, and down 4.42% year-over-year from -$10.9 million in Q4 2024.
ProQR Therapeutics' EBIAT history runs 13 years deep, the most recent figure standing at -$10.4 million for Q4 2025.
- In Q4 2025, EBIAT fell 4.42% year-over-year to -$10.4 million; the TTM figure through Dec 2025 stood at -$47.6 million (down 58.44% YoY), while the FY2025 annual figure was -$49.1 million, down 65.51% from the prior year.
- EBIAT came in at -$10.4 million for Q4 2025 at ProQR Therapeutics, up from -$12.9 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $19.0 million in Q2 2021 to a low of -$23.5 million in Q3 2022.
- A 5-year average of -$10.5 million and a median of -$10.5 million in 2025 frame the typical range for EBIAT.
- On a YoY basis, EBIAT climbed as much as 318.15% in 2021 and fell as far as 85652.29% in 2021.
- ProQR Therapeutics' EBIAT stood at -$20.9 million in 2021, then surged by 34.97% to -$13.6 million in 2022, then jumped by 56.52% to -$5.9 million in 2023, then sank by 68.55% to -$9.9 million in 2024, then decreased by 4.42% to -$10.4 million in 2025.
- According to Business Quant data, EBIAT over the past three periods registered -$10.4 million, -$12.9 million, and -$13.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 30.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | ProQR Therapeutics | 174.11 Mn | 66.54 Mn | - | -10.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -10.38 Mn |
| Sep 30, 2025 | -12.87 Mn |
| Jun 30, 2025 | -13.79 Mn |
| Mar 31, 2025 | -10.60 Mn |
| Dec 31, 2024 | -9.94 Mn |
| Sep 30, 2024 | -8.90 Mn |
| Jun 30, 2024 | -2.90 Mn |
| Mar 31, 2024 | -8.32 Mn |
| Dec 31, 2023 | -5.90 Mn |
| Sep 30, 2023 | -5.90 Mn |
| Jun 30, 2023 | -8.69 Mn |
| Mar 31, 2023 | -9.50 Mn |
| Dec 31, 2022 | -13.57 Mn |
| Sep 30, 2022 | -23.50 Mn |
| Jun 30, 2022 | -14.39 Mn |
| Mar 31, 2022 | -15.84 Mn |
| Dec 31, 2021 | -20.87 Mn |
| Sep 30, 2021 | -17.77 Mn |
| Jun 30, 2021 | 18.97 Mn |
| Mar 31, 2021 | -15.22 Mn |
| Dec 31, 2020 | -15.77 Mn |
| Sep 30, 2020 | 15.41 Mn |
| Jun 30, 2020 | 4.54 Mn |
| Mar 31, 2020 | -17,749.13 |
| Dec 31, 2019 | 20.56 Mn |
| Sep 30, 2019 | 13.57 Mn |
| Jun 30, 2019 | -13.18 Mn |
| Mar 31, 2019 | 16.19 Mn |
| Dec 31, 2018 | -14.81 Mn |
| Sep 30, 2018 | 6.97 Mn |
| Jun 30, 2018 | 8.83 Mn |
| Mar 31, 2018 | 13,166.19 |
| Dec 31, 2017 | 13.32 Mn |
| Sep 30, 2017 | 12,362.84 |
| Jun 30, 2017 | 12.49 Mn |
| Mar 31, 2017 | 11,165.46 |
| Dec 31, 2016 | -9.52 Mn |
| Sep 30, 2016 | -11.30 Mn |
| Jun 30, 2016 | -12.01 Mn |
| Mar 31, 2016 | -9.72 Mn |
| Dec 31, 2015 | -22.82 Mn |
| Sep 30, 2015 | -7,026.30 |
| Jun 30, 2015 | -7.13 Mn |
| Mar 31, 2015 | 265,510.64 |
| Dec 31, 2014 | -2.55 Mn |
| Sep 30, 2014 | 4.48 Mn |
| Mar 31, 2014 | -2.63 Mn |
| Dec 31, 2013 | -2.22 Mn |
| Sep 30, 2013 | -1.16 Mn |